Novel lead compound, called L-1, has no in vivo side effects and leads to reduced tumor growth and enhanced immune infiltration, according to research team, which reported that they “demonstrated in collaboration with colleagues at Johns Hopkins University that PTPN22 inhibition by L-1 can be further leveraged to augment antitumor effects by immune checkpoint inhibitor anti-PD1.
Researchers in Purdue University s College of Pharmacy are further developing a potential immunotherapy treatment for cancer, one focused on the mutation of an enzyme.
A possible new pathway for treating epileptic seizures in patients with autism purdue.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from purdue.edu Daily Mail and Mail on Sunday newspapers.
Neuroscience seminar highlights technologies for brain injuries, vaccine developments
The Purdue Center for Paralysis Research brings neurophysiological and engineering solutions to a trauma-themed seminar series, co-sponsored by Plexon. (Image provided)
WEST LAFAYETTE, Ind. – The same technology that helps treat traumatic brain injuries in athletes and soldiers may one day help doctors determine the effectiveness of vaccines on patients.
This technology is among the neuroscience innovations and research in the spotlight as Purdue University’s Center for Paralysis Research and Plexon Neurotechnology Systems present the Seminar for Neurotrauma and Diseases. The seminar series, which runs through April, features speakers from Purdue, Harvard Medical School and the medical industry.
New inhibitors may offer novel approach to treating deadly tuberculosis
Zhong-Yin Zhang, head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology, developed highly potent and selective compounds for use in the treatment of tuberculosis. (Image provided)
WEST LAFAYETTE, Ind. – Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.